We are live on ! Find out more

191 hedge funds and large institutions have $3.05B invested in Insmed in 2020 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 88 increasing their positions, 37 reducing their positions, and 16 closing their positions.

New
Increased
Maintained
Reduced
Closed

169% more first-time investments, than exits

New positions opened: 43 | Existing positions closed: 16

138% more repeat investments, than reductions

Existing positions increased: 88 | Existing positions reduced: 37

95% more capital invested

Capital invested by funds: $1.56B → $3.05B (+$1.48B)

82% more call options, than puts

Call options by funds: $8.24M | Put options by funds: $4.53M

25% more funds holding in top 10

Funds holding in top 10: 45 (+1)

16% more funds holding

Funds holding: 165191 (+26)

0.83% more ownership

Funds ownership: 108.78%109.61% (+0.83%)

Holders
191
Holders Change
+26
Holders Change %
+15.76%
% of All Funds
3.91%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.1%
New
43
Increased
88
Reduced
37
Closed
16
Calls
$8.24M
Puts
$4.53M
Net Calls
+$3.71M
Net Calls Change
-$3.99M

INSM Hedge Fund Activity: Q2 2020 in Review

191 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Insmed (INSM) for Q2 2020, worth a combined $3.05B — up 95% from $1.56B a quarter earlier.

Buyers outnumbered sellers: 43 funds opened new INSM positions and 16 closed out — a net gain of 27 holders — while 88 added to existing stakes and 37 trimmed.

The largest buyer was T. Rowe Price Associates, adding an estimated $61.4M. The largest seller was Point72 Asset Management, cutting an estimated $77.9M.

  • 191 institutional investors held Insmed (INSM) as of Q2 2020, up from 165 in Q1 2020.
  • Funds reported $3.05B of Insmed stock for Q2 2020, up 95% quarter-over-quarter.
  • 43 funds opened new Insmed positions in Q2 2020 and 16 closed out, a net change of +27 holders.
  • The largest Insmed buyer in Q2 2020 was T. Rowe Price Associates, an estimated $61.4M added.
  • The largest Insmed seller in Q2 2020 was Point72 Asset Management, an estimated $77.9M sold.

Based on aggregated 13F filings for Q2 2020.